CALL/VERTEX PHARMACEUTICALS/600/0.1/20.06.25 Stock CALL/VERTEX PHARMACEUTICALS/600/0.1/20.06.25
Add to a list
To use this feature you must be a member
Log inSign up

CALL/VERTEX PHARMACEUTICALS/600/0.1/20.06.25 Share Price

Warrant

DE000GG2S5R9

Market Closed - BOERSE MUENCHEN 19:26:20 28/05/2024 BST
1.45 EUR -12.65% Intraday chart for CALL/VERTEX PHARMACEUTICALS/600/0.1/20.06.25
Current month+132.74%
1 month+126.56%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart VERTEX PHARMACEUTICALS INCORPORATED
Chart CALL/VERTEX PHARMACEUTICALS/600/0.1/20.06.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing MT
Vertex to Participate in Upcoming June Investor Conferences BU
ADDvise Group’s Axelerist Bags $1.4 Million Order for Medical, Lab Equipment MT
More news

Quotes 5-day view

Date Price Change
28/05/24 1.45 -12.65%
27/05/24 1.66 +3.75%
24/05/24 1.6 +15.94%
23/05/24 1.38 +3.76%
22/05/24 1.33 +5.56%

Real-time BOERSE MUENCHEN

Last update May 28, 2024 at 07:26 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying VERTEX PHARMACEUTICALS INCORPORATED
Issuer Goldman Sachs
WKN GG2S5R
ISINDE000GG2S5R9
Date issued 18/01/2024
Strike 600 $
Maturity 20/06/2025 (388 Days)
Parity 10 : 1
Emission price 1.59 €
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.12 €
Lowest since issue 0.623 €
Delta0.24x
Omega 6.928
Premium37.69x
Gearing29.18x
Moneyness 0.7448
Difference Strike 153.1 $
Difference Strike %+25.52%
Spread 0.2 €
Spread %13.25%
Theoretical value 1.420
Implied Volatility 27.29 %
Total Loss Probability 83.97 %
Intrinsic value 0.000000
Present value 1.420
Break even 615.42 €
Theta-0.04x
Vega0.13x
Rho0.09x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
446.9 USD
Average target price
462.8 USD
Spread / Average Target
+3.57%
Consensus
  1. Stock Market
  2. Warrants
  3. Warrant